SUPERNUS PHARMACEUTICALS, INC. Preferred Stock Dividends and Other Adjustments
SUPERNUS PHARMACEUTICALS, INC. (SUPN) reported Preferred Stock Dividends and Other Adjustments of $1.14 million for the 12-month period ending 2012-12-31, per its 10-K filed 2015-03-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsAndOtherAdjustments · last filed 2015-03-12
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for the quarter ending 2012-12-31 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for the quarter ending 2012-09-30 was $0.00, a 100.00% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for the quarter ending 2012-06-30 was $286.00K, a 66.67% decline year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for the quarter ending 2012-03-31 was $858.00K, a 0.00% change year-over-year.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for fiscal 2012 was $1.14M, a 66.68% decline from fiscal 2011.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for fiscal 2011 was $3.43M, a 0.00% change from fiscal 2010.
- SUPERNUS PHARMACEUTICALS, INC. preferred stock dividends and other adjustments for fiscal 2010 was $3.43M.
| Period end | Preferred Stock Dividends and Other Adjustments 3 month | Preferred Stock Dividends and Other Adjustments 6 month | Preferred Stock Dividends and Other Adjustments 9 month | Preferred Stock Dividends and Other Adjustments 12 month |
|---|---|---|---|---|
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12 | $0.00 derived: sum of 2 quarters · filed 2015-03-12 | $286.00K derived: sum of 3 quarters · filed 2015-03-12 | $1.14M 10-K · filed 2015-03-12 |
| 2012-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $286.00K derived: sum of 2 quarters · filed 2013-11-13 | $1.14M 10-Q · filed 2013-11-13 | $2.00M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-06-30 | $286.00K 10-Q · filed 2013-08-14 | $1.14M 10-Q · filed 2013-08-14 | $2.00M derived: sum of 3 quarters · filed 2014-03-21 | $2.86M derived: sum of 4 quarters · filed 2014-03-21 |
| 2012-03-31 | $858.00K 10-Q · filed 2013-05-15 | $1.72M derived: sum of 2 quarters · filed 2014-03-21 | $2.57M derived: sum of 3 quarters · filed 2014-03-21 | $3.43M derived: sum of 4 quarters · filed 2014-03-21 |
| 2011-12-31 | $857.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21 | $1.72M derived: sum of 2 quarters · filed 2014-03-21 | $2.57M derived: sum of 3 quarters · filed 2014-03-21 | $3.43M 10-K · filed 2014-03-21 |
| 2011-09-30 | $858.00K 10-Q · filed 2012-11-02 | $1.72M derived: sum of 2 quarters · filed 2012-11-02 | $2.57M 10-Q · filed 2012-11-02 | |
| 2011-06-30 | $858.00K 10-Q · filed 2012-08-13 | $1.72M 10-Q · filed 2012-08-13 | ||
| 2011-03-31 | $858.00K 10-Q · filed 2012-06-08 | |||
| 2010-12-31 | $3.43M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |